Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Innovative medicines for the treatment of hormonally-driven cancers.
Aisling congratulates the management teams of Aragon and Seragon on their recent acquisitions by Johnson & Johnson and Genentech, respectively.
learn moreLearn More About Aragon & Seragon
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About Quintiles
Dalvance™ for the treatment of acute bacterial skin and skin structure infections.
Aisling congratulates the management team of Durata on its recent acquisition by Actavis.
Learn More About Durata
Diagnostics to accurately identify sepsis pathogens in hours instead of days.
Learn More About T2 BiosystemsAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA
May 15, 2017
NEW HAVEN, Conn., May 15, 2017 /PRNewswire/ -- (NYSE: BHVN) -- Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) announced today that the U.S. Food and Drug Administration (FDA) has granted the company Fast…
READ MORE
Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors
May 15, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2017-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that the…
READ MORE
Loxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292
May 10, 2017
STAMFORD, Conn., May 10, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that…
READ MORE